



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/810,550	03/29/2004	Nobuko Yamamoto	00862.023526.	1679
5514	7590	09/10/2010	EXAMINER	
FITZPATRICK CELLA HARPER & SCINTO 1290 Avenue of the Americas NEW YORK, NY 10104-3800			JOHANNSEN, DIANA B	
ART UNIT	PAPER NUMBER			
	1634			
MAIL DATE	DELIVERY MODE			
09/10/2010	PAPER			

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/810,550	YAMAMOTO ET AL.	
	Examiner	Art Unit	
	Diana B. Johannsen	1634	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1) Responsive to communication(s) filed on 28 June 2010.
 2a) This action is **FINAL**. 2b) This action is non-final.
 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4) Claim(s) 4-7, 50 and 51 is/are pending in the application.
 4a) Of the above claim(s) 7 and 50 is/are withdrawn from consideration.
 5) Claim(s) _____ is/are allowed.
 6) Claim(s) 4-6 and 51 is/are rejected.
 7) Claim(s) _____ is/are objected to.
 8) Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

9) The specification is objected to by the Examiner.
 10) The drawing(s) filed on _____ is/are: a) accepted or b) objected to by the Examiner.
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
 a) All b) Some * c) None of:
 1. Certified copies of the priority documents have been received.
 2. Certified copies of the priority documents have been received in Application No. _____.
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) <input type="checkbox"/> Notice of References Cited (PTO-892)	4) <input type="checkbox"/> Interview Summary (PTO-413)
2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)	Paper No(s)/Mail Date. _____ .
3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____ .	5) <input type="checkbox"/> Notice of Informal Patent Application
	6) <input type="checkbox"/> Other: _____ .

FINAL ACTION

1. This action is responsive to the Response to Election Requirement filed June 28, 2010, as well as the Amendment filed March 16, 2010. Applicant's amendments and arguments have been thoroughly reviewed, but are not persuasive for the reasons that follow. Any rejections and/or objections not reiterated in this action have been withdrawn. **This action is FINAL.** It is noted that the new grounds of rejection herein were necessitated by applicant's amendments of March 16, 2010, which (as indicated in the supplemental election requirement mailed May 26, 2010) did not include claims directed to the originally elected species of SEQ ID NO: 1 (as a result of which the newly elected combination of SEQ ID NO: 1 and SEQ ID NO: 2 are under consideration herein).
2. The text of those sections of Title 35, U.S. Code not included in this action can be found in a prior Office action.

Election/Restrictions

3. Applicant's election without traverse of the combination of SEQ ID NOS 1-2 in the reply filed on June 28, 2010 is acknowledged.
4. Claims 7 and 50 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in the reply filed on June 28, 2010.

**THE FOLLOWING ARE NEW GROUNDS OF REJECTION NECESSITATED BY
APPLICANT'S AMENDMENTS:**

Claim Rejections - 35 USC § 103

5. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

6. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

7. Claims 4-6 and 51 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hsu et al (US 2004/0010129 A1 [15 January 2004; filed 28 October 2002]) in view of Hogan et al (US 6,376,186 B1 [23 April 2002; filed 3 May 2000]).

The elected species now under consideration is the combination of SEQ ID NOS 1 and 2 (see paragraphs 3-4, above). Independent claims 4 and 5 as amended now require probe sets that include an oligonucleotide consisting of SEQ ID NO: 1 or the complement thereof, and an oligonucleotide consisting of SEQ ID NO: 2 or the complement thereof. Claim 6 (dependent from claim 5) further requires that the probe set is “chemically immobilized on a carrier”. New claim 51 (dependent from claim 4)

requires an array “on which the probe set according to claim 4 is immobilized, wherein the probe set includes the only probes on the array for detecting *Staphylococcus aureus*”.

Hsu et al disclose a set of probes “for diagnosing *Staphylococcus aureus*,” which probe set includes probes comprising instant SEQ ID NO: 1 (see entire reference, particularly, page 2 paragraphs 13 and 15 [noting the sequence identified as “1-2”, as well as claim 2) and comprising instant SEQ ID NO: 2 (see entire reference, particularly page 2, paragraphs 13 and 15 [noting the sequence identified as “1-3”, as well as claim 2). With further regard to claims 6 and 51, Hsu et al disclose biochips comprising their probe sets (see, e.g., paragraphs 18-19 and 52, and claims 23-25 and 28). Therefore, Hsu et al describe a probe, a probe set and a carrier differing from the invention of claims 4-6 only with respect to the length of the probe. With further regard to claim 51, Hsu et al teach probe combinations “for diagnosing *Staphylococcus aureus*” that are “selecting from” a group of 3 probes including the 2 noted above (see claim 2, as well as paragraphs 13, 15-16 (noting the teaching of the use of two of 3 sequences), paragraphs 18-19 and 52; claims 23-25 and 28). Thus, Hsu et al’s teachings encompass the separate use of any possible combination of their probes (including the 2 noted above).

Applicant’s claimed probe of SEQ ID NO: 1 is 6 nucleotides shorter than the probe of Hsu et al, as SEQ ID NO: 1 constitutes nucleotides 4-29 of Hsu et al’s 32-nucleotide probe. Applicant’s claimed probe of SEQ ID NO: 2 is 7 nucleotides shorter

than the probe of Hsu et al, as SEQ ID NO: 2 constitutes nucleotides 8-31 of Hsu et al's 31-nucleotide probe.

Hogan et al teach a variety of different probes for detection and quantitation of *Staphylococcus* species (see entire reference). Hogan et al disclose the use of probes of up to 100 nucleotides in length that include "at least 17 contiguous nucleotides" of a target staphylococcal sequence, as well as probes "from 17-60 nucleotides in length" (see, e.g., col 2, line 30-col 3, line 47; col 8, lines 39-54). Hogan et al provide "general guidelines" that can be "used for designing probes having desirable characteristics," and particularly suggest designing probes that are appropriate for the conditions of a particular assay, and the avoidance of probes "having extensive self-complementarity" (see col 9, line 56-col 11, line 38). Hogan et al also teach a preferred probe length of 15-50 nucleotides wherein the probes are "sufficiently homologous to the target nucleic acid to permit hybridization under high stringency conditions" (see col 11, lines 25-38).

In view of the teachings of Hogan et al, it would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to have modified the probe of Hsu et al so as to have removed 6 nucleotides from the probe "1-2" and 7 nucleotides from the probe "1-3" and thereby to have prepared the probe set of the instant claims. Hogan et al disclose that probes of a variety of lengths within the range of 15-50 or 17-60 nucleotides may be employed in detecting staphylococci, and teach that probes may be designed and/or modified to allow for hybridization under the assay conditions that a practitioner wishes to use. Thus, an ordinary artisan would have been motivated to have lengthened or shortened the probes of Hsu et al as necessary to

produce probes more desirable for use in a particular assay. More particularly, an ordinary artisan would have been motivated to have employed shorter probes, such as the probes of the claims, when performing an *S. aureus* detection assay utilizing a lower temperature and/or otherwise less stringent conditions, for the advantage of, and to achieve the predictable result of, allowing specific bacterial detection under the conditions being employed.

With further regard to the probe of SEQ ID NO: 1, additionally and/or alternatively, it is noted that the regions at each end of Hsu et al's probe encompass sequences that share self-complementarity with regions located in the center of Hsu et al's probe; see the underlined regions in "A" below with respect to the 5' end of the probe, and the highlighted regions in "B" below with respect to the 3' end of the probe:

- A. 5'-TTTGAACCGCATGGTCAAAAGTGAAGACGG-3'
- B. 5'-TTTGAACCGCATGGTCAAAAGTGAAGACGG-3'

Accordingly, an ordinary artisan would have been motivated to have made such a modification for the advantage of reducing regions of self-complementarity in the probe of Hsu et al and thereby to have increased the likelihood of successful target detection, as is explicitly taught by Hogan et al. Further, upon making such a modification to probe "1-2", an ordinary artisan would have been additionally motivated to have shortened probe "1-3" so as to facilitate its use with the modified version of probe "1-2" under conditions of similar melting temperature, and thereby to have increased the likelihood of successful detection employing both probes in a common reaction. It is noted that the Tm of each of the probes of SEQ ID NOS 1-2 (as calculated by assigning

the well known method of assigning 2° for each A/T and 4° for each G/C) is 74°C. An ordinary artisan would have readily recognized that various different modifications of probe “1-3” resulting in the adjustment of the Tm of that probe – including the particular modification resulting in instant SEQ ID NO: 2 – could be employed successfully so as to achieve the predictable result of adjusting the Tm of probe “1-3” for use in combination with modified probe “1-2”.

With further regard to claim 4 and 51, it is noted that Hsu et al teach that probes 1-2 and 1-3 may be used to differentiate *S. aureus* from each of the types of bacteria recited in claim 4 (see, e.g., paragraph 13 of Hsu et al). Further, the instant claims merely require that the claimed probe “can detect an existence of a 16s rRNA gene originating” in *S. aureus* in a sample which may contain one or more of the recited bacteria; thus, the claims encompass detection performed under any conditions of a practitioner’s choosing. Accordingly, one of ordinary skill in the art would have had a reasonable expectation that the probes suggested by Hsu et al in view of Hogan et al could be employed successfully in the manner recited in the claim, such that the probes suggested by the references meets this claim limitation. With further regard to claim 51, it is again noted that Hsu et al teach the separate use of any combination of their 3 *S. aureus* probes (as discussed above).

With regard to claims 5-6, these claims also merely require that the claimed probe set “can detect an existence of a 16s rRNA gene originating” in *S. aureus* under any conditions of a practitioner’s choosing. Thus, an ordinary artisan would also have had a reasonable expectation that the probe set suggested by Hsu et al in view of

Hogan et al could be employed successfully in the manner recited in the claim, such that the probe set suggested by the references meets this claim limitation.

Conclusion

8. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, **THIS ACTION IS MADE FINAL**. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Diana B. Johannsen whose telephone number is 571/272-0744. The examiner can normally be reached on Monday-Friday, 8:30 am-2:30 pm.

9. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dave Nguyen can be reached at 571/272-0731. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Diana B. Johannsen/
Primary Examiner, Art Unit 1634